1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Stroke - Drugs In Development, 2022, provides an overview of the Stroke (Cardiovascular) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Stroke is a condition in which the brain cells suddenly die because of a lack of oxygen. Symptoms occur rapidly and usually last a short time, from a few minutes to a couple of hours. The symptoms of a stroke usually appear suddenly. Initially the person may feel sick, and look pale and very unwell. They may complain of a sudden headache. They may have sudden numbness in their face or limbs, particularly down one side of their body. They may appear confused and have trouble talking or understanding what is being said to them. They may have vision problems, and trouble walking or keeping their balance.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Stroke - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Stroke (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Stroke (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Stroke and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 18, 38, 34, 3, 11, 152, 24 and 4 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Preclinical and Discovery stages comprises 1, 1, 34 and 5 molecules, respectively.
Stroke (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Stroke (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Stroke (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Stroke (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Stroke (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Stroke (Cardiovascular)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Stroke (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Stroke (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Stroke - Overview
- Stroke - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Stroke - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Stroke - Companies Involved in Therapeutics Development
- Stroke - Drug Profiles
- Stroke - Dormant Projects
- Stroke - Discontinued Products
- Stroke - Product Development Milestones
- Featured News & Press Releases
- Feb 17, 2017: Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Refractory Metastatic Urothelial Carcinoma and Other Genitourinary Tumors
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Stroke, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Products under Development by Universities/Institutes, 2022 (Contd..1)
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Stroke - Dormant Projects, 2022
- Stroke - Discontinued Products, 2022
- Number of Products under Development for Stroke, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 4B Technologies (Suzhou) Co Ltd
- AbbVie Inc
- Acticor Biotech SAS
- advanceCor GmbH
- Advanced BioMatrix Inc
- AegisCN LLC
- Aegle Therapeutics Corp
- Akome Biotech Ltd
- AlaMab Therapeutics Inc
- Algernon Pharmaceuticals Inc
- Allife Medical Science and Technology Co Ltd
- Anavex Life Sciences Corp
- Angion Biomedica Corp
- Ankasa Regenerative Therapeutics Inc
- Annovis Bio Inc
- Anthos Therapeutics Inc
- AntiRadical Therapeutics LLC
- Apellis Pharmaceuticals Inc
- Aposcience AG
- APstem Therapeutics Inc
- APT Therapeutics Inc
- AptaTargets SL
- Argenica Therapeutics Ltd
- AriBio
- ArmaGen Inc
- ArunA Bio Inc
- Asdera LLC
- Asha Therapeutics LLC
- AstraZeneca Plc
- Astrocyte Pharmaceuticals Inc
- Athersys Inc
- Avilex Pharma ApS
- Axolo Pharma Inc
- Band Therapeutics LLC
- Basking Biosciences Inc
- Bayer AG
- Baylx Inc
- Beijing Darwin Cell Biotechnology Co Ltd
- Beijing Yinfeng Dingcheng Bioengineering Co Ltd
- Bilix Co Ltd
- Bio-Synectics Inc
- Biogen Inc
- Biosios (Beijing) Biotechnology Co Ltd
- Bioxytran Inc
- Bolden Therapeutics Inc
- Bopin (Shanghai) Biomedical Technology Co Ltd
- Brain-Gen LLC
- Bristol-Myers Squibb Co
- Cenyx Biotech Inc
- CHA Biotech Co Ltd
- Changzhou Qianhong Bio-Pharma Co Ltd
- Chengdu Aoda Biotechnology Co Ltd
- Chengdu Shibeikang Biomedical Technology Co Ltd
- China Resources Emde Biological Pharmaceutical Co Ltd
- Clinuvel Pharmaceuticals Ltd
- Cogentis Therapeutics Inc
- CohBar Inc
- Constant Therapeutics LLC
- Creative Medical Technology Holdings Inc
- Crioestaminal Saude e Tecnologia SA
- Daewoong Pharmaceutical Co Ltd
- Deha Pharmaceutical LLC
- Diapin Therapeutics LLC
- DR.Noah Biotech Inc
- Edvince AB
- Egret Therapeutics Inc
- Eight Plus One Pharmaceutical Co Ltd
- EIP Pharma LLC
- Elevian Inc
- Emerald Organic Products Inc
- Epigen Biosciences Inc
- Epygen Biotech Pvt Ltd
- Ever Supreme Bio Technology Co Ltd
- Evgen Pharma Plc
- Exscien Corp
- F. Hoffmann-La Roche Ltd
- Fortuna Fix Inc
- Freeox Biotech SL
- FUJIFILM Toyama Chemical Co Ltd
- GABA Therapeutics Inc
- Genentech USA Inc
- Genervon Biopharmaceuticals LLC
- Glucox Biotech AB
- GNT Pharma Co Ltd
- Guangzhou Cellprotek Pharmaceutical Co Ltd
- Guangzhou Magpie Pharmaceutical Co Ltd
- Guangzhou Recomgen Biotech Co Ltd
- Guangzhou-Sheng Jian Chi Pharmaceutical Co Ltd
- Gwoxi Stem Cell Applied Technology Co Ltd
- Haimen Shengyuan Stem Cell Technology Co Ltd
- Hefei Medical & Pharmaceutical Co Ltd
- Help Therapeutics
- Hemostemix Inc
- Henan Genuine Biotech Co Ltd
- Hibernaid Inc
- Hillhurst Biopharmaceuticals Inc
- Hopstem Biotechnology LLC
- Hoth Therapeutics Inc
- Immunwork Inc
- Imstem Biotechnology Inc
- Infensa Bioscience Pty Ltd
- Inflammx Therapeutics Inc
- Instituto Biomar SA
- International Stem Cell Corp
- Io Therapeutics Inc
- IPCA Laboratories Ltd
- Jeil Pharmaceutical Co Ltd
- Jiangsu Aidea Pharmaceutical Co Ltd
- Jiangsu Carephar Pharmaceutical Co Ltd
- Jiangsu Ouwei Pharmaceutical Co Ltd
- Jiangsu Wangao Pharmaceutical Co Ltd
- JT Pharmaceuticals Inc
- Kai Nuo Bio Sci Co Ltd
- Les Laboratoires Servier SAS
- Lixte Biotechnology Holdings Inc
- LTT Bio-Pharma Co Ltd
- Lumosa Therapeutics Co Ltd
- Lys Therapeutics SAS
- M et P Pharma AG
- M3 Therapeutics Inc
- Mapreg SAS
- Marizyme Inc
- MD Healthcare Inc
- Meridigen Biotech Co Ltd
- MetiMedi Pharmaceuticals Co Ltd
- Mitoconix Bio Ltd
- Modulation Therapeutics Inc
- NA Vaccine Research Institute Co Ltd
- Nanjing Ningdan New Drug Technology Co Ltd
- NC Medical Research Inc
- NervGen Pharma Corp
- NeuExcell Therapeutics Inc
- Neuraly Inc
- Neuren Pharmaceuticals Ltd
- Neurevo GmbH
- Neurexis Therapeutics Inc
- NeurExo Sciences LLC
- Neurodon LLC
- NeuroNascent Inc
- Neurondawn pharmaceutical Co Ltd
- NeurOp Inc
- Neurophyxia BV
- NeuroTrauma Sciences LLC
- New World Laboratories Inc
- Nipro Corp
- NoNO Inc
- Novago Therapeutics AG
- Novartis AG
- NuvOx Pharma LLC
- Nyrada Inc
- Oasis Pharmaceuticals LLC
- Omniox Inc
- OTR3 SAS
- Oxitope Pharma BV
- Palisade Bio, Inc
- Paracelsus Neuroscience I LLC
- Pharmadrug Inc
- Pharmagenesis Inc
- PharmaTher Holdings Ltd
- PharmatrophiX Inc
- Pharmazz Inc
- Pharmicell Co Ltd
- Pharming Group NV
- Phoenix Biotechnology Inc
- PhytoHealth Corp
- Prediction BioSciences SAS
- Primary Peptides Inc
- Prolong Pharmaceuticals LLC
- Protheragen Inc
- Q Therapeutics Inc
- Q32 Bio Inc
- Qingdao Primedicine Pharmaceutical Technology Co Ltd
- Regenera Pharma Ltd
- Regeneron Pharmaceuticals Inc
- RegeneRx Biopharmaceuticals Inc
- Reliance Life Sciences Pvt Ltd
- Remedium Bio Inc
- ReNetX Bio
- ReNeuron Group Plc
- Revalesio Corp
- Revive Therapeutics Ltd
- Rubicon Biotechnology Inc
- S&E Bio Co Ltd
- S.Biomedics Co Ltd
- Saillant Therapeutics BV
- Saje Pharma LLC
- SanBio Co Ltd
- Saneron CCEL Therapeutics Inc
- Saniona AB
- Sansho Co Ltd
- Savara Inc
- Sentan Pharma Inc
- Serenity Bioworks Inc
- Shanghai Hutchison Pharmaceuticals Ltd
- Shanghai SIMR Biotech Co Ltd
- Shanghai Zhimeng Biopharma Inc
- Shijiazhuang Yiling Pharmaceutical Co Ltd
- Shimao Tianjie Pharmaceutical (Jiangsu) Co Ltd
- Shin Poong Pharm Co Ltd
- Shionogi & Co Ltd
- Silver Creek Pharmaceuticals Inc
- Simcere Pharmaceutical Co Ltd
- SL Bigen Co Ltd
- SNJ Pharma Inc
- Stemedica Cell Technologies Inc
- Stemetix Inc
- Stream Biomedical Inc
- SunBio Inc
- Suzhou Auzone Biological Technology Co Ltd
- Suzhou Pharmavan Cancer Research Center Co Ltd
- Synaptogenix Inc
- TagCyx Biotechnologies
- TargED Biopharmaceuticals BV
- Tasly Pharmaceutical Group Co Ltd
- Techfields Pharma Co Ltd
- The Cell Factory BVBA
- Theertha Biopharma Pvt Ltd
- TheraSource LLC
- Theratome Bio Inc
- Thrombolytic Science International LLC
- TikoMed AB
- Translational Sciences Inc
- TrueBinding Inc
- Valin Technologies Ltd
- Vanworld Pharmaceutical (Rugao) Company Ltd
- Vect-Horus SAS
- Venturis Therapeutics Inc
- Verseon Corp
- Virogenomics BioDevelopment Inc
- Virtici LLC
- Vitro Biopharma Inc
- Vivazome Therapeutics Pty Ltd
- XBiotech Inc
- Xonovo Inc
- Yantai YenePharma Co Ltd
- YouCare Pharmaceutical Group Co Ltd
- Zensun (Shanghai) Sci & Tech Co Ltd
- Zhejiang Ausun Pharmaceutical Co Ltd
- Zhittya Genesis Medicine Inc
- Zocere Inc
- ZyVersa Therapeutics Inc
- ZZ Biotech LLC
